Skip to main content
padlock icon - secure page this page is secure

Trends in Patents of Enzymatic Biomarkers for Early Detection of Bacteria

Buy Article:

$68.00 + tax (Refund Policy)

Delayed or improper diagnosis of bacterial infection can result in sepsis, serious, and often deadly or inflammatory response. Thus, there is a need for a simple assay that can detect low levels of bacteria, which are faster and sensitive in order to provide data for establish treatment decisions in a clinically relevant time frame. Advances in materials research and molecular biology play an important role in understand and development the best way for bacterial diagnosis kits and methods to reach specific targets from the cellular metabolism such as particular enzymes. Recent changes in the diagnostic methods are using simple techniques especially focus to distinguish enzymatic reactions, dependent on substrate and biochemical allowing the bacteria presence detection by very fast reactions. This review highlights the state-ofart in patents of enzymatic biomarkers for early detection of bacteria based-on nanostructures chromogenic or fluorogenic.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Bacteria; Coumarin derivatives; Enzyme-substrates; Nanostructures; chromogenic; diagnosis; early detection; enzymatic biomarkers; fluorogenic; nanodevices

Document Type: Research Article

Publication date: January 1, 2013

More about this publication?
  • Recent Patents on Biomarkers publishes review and research articles, and guest edited thematic issues on important recent patents on biomarkers. The coverage includes novel biomarkers in basic, medical, environmental, and pharmaceutical research. A selection of important and recent patents on biomarkers is also included in the journal. The journal is essential reading for all researchers involved in biomarker research and discovery. The journal also covers recent research (where patents have been registered) in fast emerging patent biomarker applications; discovery and validation are covered for drug discovery, clinical development and molecular diagnostics.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more